Global Pancreatic Cancer Drugs Market

The cancer diagnostics market consists of sales of cancer diagnostic devices and equipment. Cancer diagnostic equipment is used to identify biomarkers, proteins, and symptoms to detect a cancerous tumor in the patient. The main products in cancer diagnostics are companion diagnostics and molecular diagnostics. Molecular diagnostics is a laboratory method that is used to check for certain proteins, genes, or other molecules that may be a sign of cancer. The methods used in cancer diagnostics are biopsy, endoscopy, tumor biomarker tests, and imaging. The applications covered in cancer diagnostics are cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others that are used by end-users such as cancer research institutes, diagnostic laboratories, hospitals, and others. The global cancer diagnostics market size is expected to grow from $17.2 billion in 2021 to $19.18 billion in 2022 at a compound annual growth rate (CAGR) of 11.5%. The global cancer diagnostics market size is expected to grow to $29.64 billion in 2026 at a CAGR of 11.5%. A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers are leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030. Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older. The AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%. The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into the Class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, post market surveillance, and labeling requirements associated with their usage. For instance, the labeling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings, and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices. Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd, GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Illumina, Elekta AB, and C.R. BardInc. North America was the largest region in the cancer diagnostics market in 2021. Asia Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the global cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global cancer diagnostics market is segmented - 1) By Product: Companion Diagnostics, Molecular Diagnostics 2) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Others 3) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging 4) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Others

The cervical cancer diagnostics market consists of sales of cervical cancer diagnostic devices and related services by entities (organizations, sole traders, and partnerships) that produce cervical cancer diagnostics devices. Cervical cancer is a type of cancer that occurs in cells of the cervix. These devices are used for the diagnosis of cervical cancer. The main types of cervical cancer diagnostics are pap smear tests, HPV tests, colposcopy, biopsy, endocervical curettage, and other diagnostic tests. The pap smear test is the process of testing cervical cancer in women. The age group involved are below 21, age between 21 to 29, age between 30 to 65, and above 65. The end-users involved are hospitals, specialty clinics, cancer and radiation therapy centers, and diagnostic centers. The global cervical cancer diagnostics market size is expected to grow from $7.78 billion in 2021 to $8.29 billion in 2022 at a compound annual growth rate (CAGR) of 6.7%. The global cervical cancer diagnostic market is expected to grow to $10.54 billion in 2026 at a CAGR of 6.2%. The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. For instance, in August 2019, the United States Preventive Services Task Force has updated its screening guidelines for cervical cancer, which specifies that women between ages 21 to 29 should be screened with a Pap test every 3 years, women between ages 30 to 65 should be screened with any of three tests, namely high-risk HPV testing alone, Pap and high-risk HPV contesting for every 5 years and Pap test alone for every 3 years. The rising adoption of cervical cancer diagnostic tests and emphasis on early diagnosis propels the market. The increased use of HPV vaccination is anticipated to hinder the cervical cancer diagnostics market. According to the World Health Organization, the 2 HPV types (16 and 18) cause 70% of cervical cancers and pre-cancerous cervical lesions, thereby giving human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical pre-cancerous lesions that may develop into cervical cancers. The study published in Cancer Epidemiology, Biomarkers & Prevention, in February 2019 supported the information from the Centers for Disease Control and Prevention (CDC) that states that among women who had been vaccinated, the share of precancers caused by HPV 16 and 18 dropped from 55.2% to 33.3% whereas, in unvaccinated women, the proportion dropped from 51% to 47.3%. The HPV vaccine is recommended by the Centers for Disease Control and Prevention (CDC) for all kids and adults between the ages of 9 to 26. Therefore, the increased use of HPV vaccination is predicted to hinder the cervical cancer diagnostics market. The increased adoption of HPV home testing kits is expected to be the new trend in the market. The home-based HPV testing kits help women in collecting samples and getting the results conveniently on their own without going to the lab for screening. Therefore, companies are focusing on providing convenience to patients. For instance, in January 2019, Nurx, a consumer health and telemedicine company, introduced lab testing that allows women to easily and affordably monitor their risk of cervical cancer from the comfort of their homes. Similarly, in April 2019, Matter introduced three conceptual cervical cancer examinations through the Sukha project that help women carry out tests at home to break the stigma associated with cervical testing. In May 2020, The USA-based firm, Becton, Dickinson & Co, a manufacturer and seller of medical devices, instrument systems, and reagents announced the acquisition of San Diego biomedical business CareFusion for $12.2 billion. The acquisition is expected to improve the quality of patient care and reduce health care costs by identifying the needs in hospitals, hospital pharmacies, and alternate sites of care. Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co, Bio-Rad Laboratories Inc, F. Hoffmann-La Roche Ltd, Hologic Inc, QIAGEN NV, Quest Diagnostics Inc, Siemens Healthineers AG, Zilico, and Guided Therapeutics. North America was the largest region in the cervical cancer diagnostics market in 2021. Asia Pacific was the second largest region in the global cervical cancer diagnostics market. The regions covered in the global cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cervical cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global cervical cancer diagnostics market is segmented - 1) By Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Others 2) By End-User: Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres, Diagnostic Centres 3) By Age Group: Below 21, Age between 21 to 29, Age between 30 to 65, Above 65

Brain Tumor Drugs Market Definition

The brain tumor drugs market consists of sales of brain tumor drugs and related services by entities (organizations, sole traders and partnerships) that produce brain tumor drugs to diagnose and cure a mass growth of abnormal cells in the human brain. These drugs are either used alone or in combinations, depending on the type, size and location of the tumor. For example, Afinitor (Everolimus), BiCNU (Carmustine), Everolimus, Carmustine, Temozolomide and Avastin (Bevacizumab) are some of the drugs included in this market. The pharmaceutical industry develops drugs to diagnose, treat or prevent diseases. Pharmaceutical drugs are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy, and marketing. Brain tumor drugs manufacturers produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.

The bladder cancer drugs market consists of sales of bladder cancer drugs. Bladder cancer is cancerous tissue that occurs on the lining of the bladder. These cancerous tissues are also called tumors and have the potential to spread to other nearby cells and tissues if not treated soon. The bladder cancer market consists of treatments of bladder cancer types such as urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma and others. The main types of bladder cancer drugs are non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. NMIBC (non-muscle invasive bladder cancer) is cancer that develops in the tissue that lines the bladder’s inner surface. There is no involvement of the bladder muscle. The different applications include low-grade tumors, high-grade tumors and distributed through various channels such as hospital pharmacy, retail pharmacy, others. The global bladder cancer drugs market size is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global bladder cancer drug market size is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%. The number of bladder cancer cases has been on the rise. Factors such as unhygienic workplace exposures, increase in smoking habits and consuming water that contains Arsenic increases the chances of blood cancer. According to American Cancer Society, there were 81,400 new cases of bladder cancer in 2020 out of which a total of 62,100 cases were in men and 19,300 cases in women. This increased incidence of bladder cancer increases the demand for bladder cancer drugs, contributing to the growth of the market. Increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. For instance, FDA cleared targeted therapy, Tecentriq, a first product in its class (PD-1/PD-L1 inhibitors) approved to treat bladder cancer. The advantages of biologics drugs and targeted therapies over conventional chemical drugs might negatively influence the market. Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells. For instance, in February 2019, the Center for Drug Research And Development in Canada has pledged a $1.2 million investment in Sitka biopharma to help with development activities for clinical trials of STK-01, a product to treat bladder cancer using nanotechnology. The bladder cancer drugs market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others which lay down policies and guidelines that a manufacturer should follow. For instance, in the USA, FDA has formulated three main programs for expediting drugs that could be used to treat serious conditions, namely the fast-track program, the breakthrough drug program, and the accelerated approval program. Though these three programs are used in expediting the approval of drugs, there subtle differences. Fast track status is given to a drug that can treat a serious condition and clinical/non-clinical data prove its potential to cater to unmet medical needs. Breakthrough therapy status is given to a drug that can treat a serious condition and there is proper clinical evidence of it being better than available treatments. Accelerated approval status is given to a drug that has breakthrough therapy status along with a surrogate endpoint that can predict its effectiveness. A surrogate endpoint is an indicator or sign that can be used to tell if a treatment method is effective or not. For example, in cancer treatments a shrinking tumor can be used as an indicator of cancer treatment effectiveness than checking for time of tumor survival. Surrogate endpoints are used in clinical trials to save time and is especially used in the fast expedition of life-saving drugs. FDA expedites drugs under all three programs within 60 days of filing a request for consideration. In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction helps Bristol-Myers acquire a bigger market share of immuno-oncology drugs including bladder cancer drugs in the USA and compete with its competitors. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA. Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, Hoffmann-La Roche, Novartis International and Johnson & Johnson. North America is the largest region in the bladder cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the bladder cancer drug market during the forecast period. The regions covered in the bladder cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bladder cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global bladder cancer drugs market is segmented - 1) By Type: Non-Muscle-Invasive Bladder Cancer, Muscle-Invasive Bladder Cancer 2) By Application: Low-Grade Tumors, High-Grade Tumors 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others

The prostate cancer drugs market consists of sales of various drugs used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy and targeted therapy. The different types of prostate cancer drugs are hormone sensitive prostate cancer and hormone refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) is a kind of prostate cancer that no longer responds to hormone therapy, even newer treatments. The different types of therapies include hormonal therapy, chemotherapy, immunotherapy, targeted therapy and involves various sectors such as hospitals, clinics, others. The global prostate cancer drugs market size is expected to grow from $16.09 billion in 2021 to $17.64 billion in 2022 at a compound annual growth rate (CAGR) of 9.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global prostate cancer drug market is expected to reach $23.95 billion in 2026 at a CAGR of 8.0%. The increasing male geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to the United Nations (UN), there were around 703 million people aged 65 or above globally, accounting for 13% of the global population in 2019. The American Cancer Society's statistics for prostate cancer in the USA states that about 6 prostate cancer cases in 10 are diagnosed in men aged 65 or above, and it is rare for men aged less than 40. Recurrent/non-responsive prostate cancer is major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to recurrence or spread of the cancer after an initial treatment. Prostate cancer can recur locally in the tissue next to the prostate, the surrounding lymph nodes in the pelvis or lymph nodes outside this area, tissues next to the prostate (such as the muscles that help control urination, the rectum, or the wall of the pelvis). The cancer can also travel through the bloodstream and recur in bones or other organs. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment. The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer. The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for approval of new drugs and lays down regulations related to treatment of prostate cancer. For instance, the FDA approved Erleada (apalutamide) for the treatment of prostate cancer that has not spread (non-metastatic), but continues to grow despite treatment with hormone therapy (castration-resistant). This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market. In June 2021, Bayer, a Germany based pharmaceutics company acquired Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc for an undisclosed amount. With this acquired Bayer will gain exclusive access to a specialized alpha radionuclide investigational drug built on actinium-225 and a small molecule aimed against prostate-specific membrane antigen. PSMA Therapeutics Inc. is a US-based company that specializes in prostate-specific membrane antigen research and Noria Therapeutics Inc. is a radiotherapy firm focused on creating alpha-emitting radiopharmaceuticals for targeted therapeutic and imaging applications in oncology. Major players in the prostate cancer drugs market are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG, Roche, Abbott, Pfizer, Norvaris and F. Hoffmann-La Roche AG. North America is the largest region in the prostate cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global prostate cancer drug market during the forecast period. The regions covered in the global prostate cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global prostate cancer drugs market is segmented - 1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer 2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy 3) By End-User: Hospitals, Clinics, Others

The skin cancer drugs market consists of sales of skin cancer drugs. Skin Cancer is an unrestricted growth of abnormal skin cells that lead skin cells to proliferate rapidly and form malignant tumors. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma or melanoma. Examples of skin cancer drug include 5-FU, Aldara and Efudex. The main types of skin cancer drugs are actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and melanoma. Actinic keratoses is a broad, rough skin patch which can turn cancerous. It commonly appears on sun-exposed regions such the face, scalp, backs of the hands, and chest. It is especially common in fair-skinned persons. Solar keratosis and senile keratosis are two terms for the same condition. The different classes of drugs include chemotherapy, immunotherapy, targeted agents & other drugs and is used in various sectors such as hospitals, cancer research centers, clinics. The global skin cancer drugs market size is expected to grow from $2.62 billion in 2021 to $3.06 billion in 2022 at a compound annual growth rate (CAGR) of 17.0%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global skin cancer drug market is expected to reach $5.39 billion in 2026 at a CAGR of 15.2%. Significant rise in prevalence of skin cancer is driving the demand for the drugs for Skin Cancer. To treat such high cases of skin cancer, more number of new innovative skin cancer drugs is being manufactured. According to the American Academy Of Dermatology, in 2019, there were 192,310 new cases of Melanoma type skin cancer. Additionally, non-invasive type skin cancer count could rise to 95,830 and 96,480 invasive skin cancer could be diagnosed in US in 2019. According to the American Academy Of Dermatology, each year roughly around 3 million Americans get diagnosed by skin cancer. This is boosting the demand for skin cancer drugs and thus driving the market. Increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs targets melanoma cells only. The chemical drugs attack any fast-dividing cells while targeted therapies only attack the skin cancer causing melanoma cells. Thus, doctors are preferring targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the market going forward. Companies in the skin cancer market are increasingly looking for strategic alliances with other companies in the market. Strategic alliances help companies to enhance their R&D capability, expedite the development process of new drugs and reinforce competitive position in the market. For example, Leo Pharma has formed a strategic alliance with PellePharm, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies pertaining to the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug pertaining to skin cancer. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. The EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. The EMA also educates the patients regarding the risks associated in taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, benefits of the drug and all other relevant information pertaining to such drugs. In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. This acquisition would help Bristol-Myers Squibb to widen its portfolio of drug in skin cancer market. This acquisition would also help Bristol-Myers Squibb to expedite the development of new innovative drugs which are in the early stages of drug pipeline. Celgene is an innovative biotechnology company that manufactures and develops cancer drugs. Celgene was founded in 1986 and is headquartered at Summit, New Jersey, United States. Major players in the skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd, Roche, Aqua Pharmaceuticals, Bausch Health, GlaxoSmithKline PLC and Pfizer Inc. North America is the largest region in the skin cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the global skin cancer drug market during the forecast period. The regions covered in the global skin cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the skin cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global skin cancer drugs market is segmented - 1) By Type: Actinic Keratoses (AK), Basal Cell Carcinoma (BCC), Squamous Cell Carcinoma (SCC), Melanoma 2) By End-User: Hospitals, Cancer Research Centers, Clinics 3) By Drug Class: Chemotherapy, Immunotherapy, Targeted Agents and Other Drugs

The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer. The ovarian cancer drugs include Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, Platinol (Cisplatin), Paraplatin (Carboplatin), Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide) and others. The main types of tumors in ovarian cancer drugs are epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, sex cord-stromal tumor. The most frequent kind of ovarian cancer is epithelial ovarian cancer. The majority of ovarian tumours (90 percent) are epithelial. Ovarian cancer that began in the epithelial layer protecting the ovary is known as epithelial ovarian cancer. The different types of drugs include alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, vegf/vegfr inhibitors, parp inhibitors, antineoplastics, others and distributed channels such as hospital pharmacies, drug stores, others. The global ovarian cancer drugs market size is expected to grow from $2.68 billion in 2021 to $3.25 billion in 2022 at a compound annual growth rate (CAGR) of 21.2%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global ovarian cancer market size is expected to reach $6.58 billion in 2026 at a CAGR of 19.3%. The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a study by The World Ovarian Cancer Coalition an estimated 55% rise is expected in the number of patients suffering from ovarian cancer by 2035. According to the Cancer Statistics in 2020, published by the American Cancer Society’, about 1,806,590 new cancer cases and 606,520 deaths were expected in USA. Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth. Increasing use of biologics and targeted therapies are restraining the Ovarian Cancer drugs market growth. Targeted therapies act as substitutes for drugs as they identify and attack cancer cells rather than destroying normal cells. For example, Bevacizumab is a targeted therapy biologics drugs used to treat Ovarian Cancer. A targeted therapy drug, Zejula was approved by FDA for ovarian cancer, and many targeted therapy drugs such as PARP inhibitors (targeted therapy drug) are undergoing clinical trials and are in drug pipeline. FDA has also approved Genentech’s biologics license for ovarian cancer drugs highlighting the fact many new companies are entering into the biologics ovarian drug cancer market. Hence, the growing popularity of alternatives such as biologics and targeted therapies may hinder the growth of ovarian cancer drugs market. Drug manufacturing companies in the industry are increasingly innovating and developing combination drugs to treat ovarian cancer drugs. Combination drugs consists of two or more active pharmaceutical ingredients (APIs) that are combined into a single dosage form to treat complex medical conditions. The pharmaceutical companies in the ovarian cancer drugs market are investing on the research and development of innovative products such as combination drugs to reduce manufacturing costs, increase compliance and efficiency, improve medication concordance, increase profitability and reduce side effects. For instance, Roche's blockbuster tranquilize Avastin (bevacizumab), is a combination drug approved by FDA, with ingredients such as carboplatin and paclitaxel, which is utilized to treat advance stage (III or IV) ovarian cancer. The ovarian cancer drugs market is governed by regulatory framework of agencies such as Food and Administration Agency (FDA) and American Society of Clinical Oncology (ASCO). FDA's recommendation for ovarian cancer drugs market in the form of guidelines are mentioned within the CFR 's (Code for Federal Regulations) title number 21 under part 312, that contains sub-parts from sub part 'A' to sub part 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as kidney cancer. The sub part 'E' also includes guidelines for the monitoring and evaluation of clinical trials of ovarian cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in ovarian cancer drugs industry are required to abide to the regulations under FDA. In January 2019, GlaxoSmithKline (GSK), a UK-based pharmaceutical company, acquired Tesaro for $5.1 billion. This acquisition would enable GSK to expand its product portfolio with Tesaro’s Zejula, PARP inhibitor and others, improve significant opportunities in strengthening GSK’s pharmaceutical business by accelerating the build of GSK’s pipeline and commercial capability in oncology. Tesaro, a biopharmaceutical (oncology-focused) company, is involved in manufacturing and marketing ovarian cancer drugs such as Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor and others, that aid in treating ovarian cancer. Tesaro was founded in 2010 and headquartered in Waltham, Massachusetts, USA. Major players in the ovarian cancer drugs market are AstraZeneca, Roche, Tesaro, Clovis Oncology, Boehringer Ingelheim, Amgen, GlaxoSmithKline, F. Hoffmann-La Roche AG, Bristol-Myers Squibb and Eli Lilly and Company. North America is the largest region in the ovarian cancer drugs market in 2021. The Middle East is expected to be the fastest growing region in the ovarian cancer drug during the forecast period. The regions covered in the ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ovarian cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global ovarian cancer drugs market is segmented - 1) By Tumor Type: Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor 2) By Distribution Channel: Hospital Pharmacies, Drug Stores, Others 3) By Drug Type: Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR Inhibitors, PARP Inhibitors, Antineoplastics, Others

The cancer biologics market consists of sales of cancer biologics. Cancer biologic drugs are the products that are produced from living organisms or contain components of a living organisms. Biologic drugs include a wide variety of products which are derived from human, animal or microorganisms by using biotechnology. The main types of cancer biologics are monoclonal antibodies, vaccines, cell and gene therapy, others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. It is used in non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancers, others and distributed through various channels such as hospitals, clinics, others. The global cancer biologics market size is expected to grow from $76.46 billion in 2021 to $86.64 billion in 2022 at a compound annual growth rate (CAGR) of 13.3%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cancer biologics market is expected to reach $129.05 billion in 2026 at a CAGR of 10.5%. Rising prevalence of chronic diseases is one of the major factors driving the cancer biologics market growth. Chronic disorders are the diseases which persists over a long period of time and hinder the health of people with disabilities and cancer is one of the common chronic diseases. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. According to World Health Organization (WHO), in 2020 chronic diseases accounted for 75% of deaths globally. Therefore, the rising prevalence of chronic diseases is expected to drive the growth of the cancer biologics market over coming years. The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics. Biologic drugs are administered by injection or infusion as they are proteins which are quickly digested and inactivated if given by mouth so they can cause injection site reactions or infusion reactions. Moreover, the adverse effects of the biologics vary from common side effects such as allergic reactions and diarrhoea to serious adverse effects such as low blood pressure, hepatitis and hypothyroidism. For instance, according to a study conducted by NCBI, biological agents are essential additions to chemotherapy for GI malignancies that leads to enhanced survival response rates but these additions also bring some unique adverse reactions to the patients. Companies in the cancer biologics market are developing predictive biomarkers which help the physicians to decide the treatments for their patients by utilizing physiological biomarkers for predicting the performance. Predictive biomarkers study tumor growth in patients by analyzing the major etiological factors as the cancer etiology differs from patient to patient. Moreover, these biomarkers not only aid in the early detection of cancer but also help in deciding the cost-effective treatment regimens, especially for the biologics based on gene therapy. According to FDA approval process of new cancer treatment and biological products, the application for the approval should include all relevant data available from clinical studies, including negative results as well as positive findings. Data can come from pharmaceutical company sponsored clinical trials intended to test the safety and effectiveness of a new use of a product, or from a number of alternative sources. In May 2019, Evotec SE, drug discovery and development solutions provider acquired Just Biotherapeutics, Inc. for $90 million. The acquisition will help Evotec's business to grow into offering the biologics into the therapeutic areas such as oncology. Just Biotherapeutics is a US-based unique technology company that integrates highly synergistic scientific expertise and ML driven technologies for development and manufacturing of biologics at highest standards. Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis and Pfizer. North America was the largest region in the cancer biologics market in 2021. The Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cancer biologics market is segmented - 1) By Type: Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Others 2) By Application: Non-Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Others 3) By Distribution Channel: Hospitals, Clinics, Others